Cefditoren Pivoxil
An oral third-generation cephalosporin antibiotic prodrug that is hydrolyzed in the intestinal wall to the active cefditoren. It is used to treat community-acquired pneumonia, acute exacerbations of chronic bronchitis, and skin infections. The pivoxil moiety releases pivalic acid during absorption, which may interfere with carnitine metabolism with prolonged use.
Peso molecular
620,7000 g/mol
LogP
4,70
TPSA
257,00 Ų
Regla de cinco de Lipinski
No cumple
Mecanismo de acción
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Estructura 2D
Cite this structure
Embed this structure
SMILES
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)OCOC(=O)C(C)(C)C)=C(/C=C\c3scnc3C)CS[C@H]12)c1csc(N)n1
InChI
InChI=1S/C25H28N6O7S3/c1-12-15(41-10-27-12)7-6-13-8-39-21-17(29-19(32)16(30-36-5)14-9-40-24(26)28-14)20(33)31(21)18(13)22(34)37-11-38-23(35)25(2,3)4/h6-7,9-10,17,21H,8,11H2,1-5H3,(H2,26,28)(H,29,32)/b7-6-,30-16-/t17-,21-/m1/s1
Molecular Formula
C25H28N6O7S3
HBD / HBA
2 / 14
Enlaces Rotables
12
Átomos Pesados
41
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
An oral third-generation cephalosporin antibiotic prodrug that is hydrolyzed in the intestinal wall to the active cefditoren. It is used to treat community-acquired pneumonia, acute exacerbations of chronic bronchitis, and skin infections. The pivoxil moiety releases pivalic acid during absorption, which may interfere with carnitine metabolism with prolonged use.
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Yes, Cefditoren Pivoxil is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL454446. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 6437877. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cefditoren-pivoxil"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cefditoren-pivoxil/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cefditoren-pivoxil/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cefditoren-pivoxil/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cefditoren-pivoxil"></drugfyi-drug>